Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Short-term Investments (2017 - 2025)

Anaptysbio (ANAB) has disclosed Short-term Investments for 9 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 72.0% year-over-year to $73.4 million, compared with a TTM value of $73.4 million through Dec 2025, down 72.0%, and an annual FY2025 reading of $73.4 million, down 72.0% over the prior year.
  • Short-term Investments was $73.4 million for Q4 2025 at Anaptysbio, down from $139.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $394.3 million in Q2 2023 and bottomed at $60000.0 in Q1 2021.
  • Average Short-term Investments over 5 years is $240.2 million, with a median of $270.6 million recorded in 2024.
  • The sharpest move saw Short-term Investments crashed 99.97% in 2021, then soared 640598.33% in 2022.
  • Year by year, Short-term Investments stood at $52.4 million in 2021, then surged by 606.41% to $369.9 million in 2022, then decreased by 4.05% to $354.9 million in 2023, then fell by 26.1% to $262.3 million in 2024, then plummeted by 72.0% to $73.4 million in 2025.
  • Business Quant data shows Short-term Investments for ANAB at $73.4 million in Q4 2025, $139.1 million in Q3 2025, and $221.4 million in Q2 2025.